Chemo Stability Chart - LtoZ

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART
DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special
(Storage Prior to Use, With: Stability Precautions/Notes
Manufacturer, Preservative
Status)
Leucovorin
1 1,2
50 mg/5 mL N/A 10 mg/mL discard unused syringe 8 h RT
1
(GMP) portion
(F)(PFL)
1
no preservative 0.05-10 mg/mL NS, D5W, LR,
NS, D5W, Ringer’s, Ringer’s:
1
LR, D10W, 24 h RT
1,2
D5-NS
D10W, D5-NS:
1
(e.g., 50-250 mL*) 8 h RT
Leucovorin
3 3 3
50 mg/5 mL N/A 10 mg/mL 8h syringe 8 h RT
500 mg/50 mL
(Pfizer/Hospira)
(F)(PFL) 0.05–10 mg/mL NS, NS, D5W, LR,
3
no preservative D5W, LR, Ringer’s, Ringer’s:
3 3
D10W, D5NS 24 h RT
(e.g., 50-250 mL*) D10W, D5NS:

3
8 h RT
BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 1/41
This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy.
Activation Date: 2 March 2006
Revised Date: 1 December 2019
Status)
Leucovorin
5 6,7
50 mg/5 mL N/A 10 mg/mL discard unused syringe 8h
5
500 mg/50 mL portion
(Teva)
(F)(PFL)
4 8
no preservative 0.4 - 4.8 mg/mL NS, 72 h F, RT
8
D5W
(e.g., 50-250 mL*)
0.06 - 0.4 mg/mL NS, NS:

4 4
D5W 24 h RT
D5W:
4
12 h RT
0.06 - 1 mg/mL Ringer’s, LR:

4
Ringer’s, Lactated 24 h RT
Ringer’s, D10W,
4
D10-NS D10W:
4
12 h RT
D10NS:
4
6 h RT
Status)
Melphalan
9 9
50 mg 10mL supplied 5 mg/mL 2 h RT 0.1 – 0.45 mg/mL in complete
9 9
(GSK) diluent NS only administration within
(RT)(PFL) do NOT 60 min from time of
9
no preservative immediately after refrigerate (e.g., greater than 45 initial reconstitution at
10
adding diluent, mg and less than or RT
9
shake vigorously equal to 110 mg in
250 mL NS)*
record time of
reconstitution
Mesna
11 11
400 mg/4 mL N/A 100 mg/mL discard unused greater than 1 mg/mL 24 h RT
11
1000 mg/10 mL portion in D5W, D5½-NS,
11-13
(Baxter) (use filter needle to NS, LR
(RT) withdraw from
11
no preservative ampoule)
Mesna
11 11 11
1000 mg/10 mL N/A 100 mg/mL 8 days RT greater than 1 mg/mL 24 h RT
5000 mg/50 mL in D5W, D5½-NS,
11-13
(Baxter) (vial may be NS, LR
(RT) punctured up to 4
11 11
preservative times)
Mesna
14 14,15 14
1000 mg/10mL N/A 100 mg/mL 14 d F, RT greater than or equal 24 h RT, 48 h F
(Fresenius Kabi) to 1 mg/mL in NS,
16
(RT) D5W
14
preservative
Status)
Methotrexate
17
50 mg/2mL N/A 25 mg/mL 50mg: syringe use within 8 h RT of - for high-dose
17
500 mg/20mL discard unused initial puncture regimens (e.g., 1-
17 2
1 g/40mL portion 12 g/m as a single
18-22
(Accord) dose) : use
(RT)(PFL) 500 mg or 1 g: 0.4–2 mg/mL NS, use within 24 h RT of preservative-free
17 17 17 17 17
no preservative 8 h RT D5W initial puncture methotrexate
- do not use for IT
(100 mL* NS, D5W) **(PFL) injection
high dose use within 24 h RT of

2 17
(e.g., 1-12 g/m as a initial puncture
18-22
single dose) : 1000
mL* NS **(PFL)
Methotrexate
17 2
IT Injection N/A 25 mg/mL discard unused qs to 6 mL with use within 4 h of initial - auxiliary info
17 2
Only preservative free portion preservative free puncture - label to include
24,25
methotrexate may be NS route in full (i.e.,
administered by the INTRATHECAL
23
intrathecal route injection) attached
50 mg/2mL to both syringe and
26
(Accord) outer ziplock bag
(RT)(PFL)
17
no preservative
Status)
Methotrexate
17 2,17 2
50 mg/2mL N/A 25 mg/mL 14 d F syringe 14 d F - contains benzyl
17
500 mg/20mL alcohol
(Accord) - do NOT use for
(RT)(PFL) 0.4–2 mg/mL NS, 24 h RT
17 high-dose
17
preservative D5W
17 regimens (e.g., 1-
2
12 g/m as a single
17
(100 mL* NS, D5W) dose)
- do NOT use for IT
17
injection
Methotrexate
27
50 mg/2mL N/A 25 mg/mL 50mg: syringe use within 8 h RT of - for high-dose
27
500 mg/20mL discard unused initial puncture regimens (e.g., 1-
27 2
1 g/40mL portion 12 g/m as a single
18-22
2.5 g/100 mL dose) : use
(Pfizer/Hospira) 500 mg, 1 g, or 0.4–2 mg/mL NS, use within 24 h RT of preservative-free
27 27 27
(RT)(PFL) 2.5 g: D5W initial puncture methotrexate
27 27
no preservative 8 h RT - do not use for IT
(100 mL* NS, D5W) **(PFL) injection
high dose use within 24 h RT of

2 27
(e.g., 1-12 g/m as a initial puncture
18-22
single dose) : 1000
mL* NS **(PFL)
Status)
Methotrexate
27 2
IT Injection N/A 25 mg/mL discard unused qs to 6 mL with use within 4 h of initial - auxiliary info :
27 15
Only preservative free portion preservative free puncture “IT”
24,25
methotrexate may be NS - label to include
administered by the route in full (i.e.,
23
intrathecal route INTRATHECAL
50 mg/2mL injection) attached
(Pfizer/Hospira) to both syringe and
26
(RT)(PFL) outer ziplock bag
27
no preservative
Methotrexate
27 15,27 15
50 mg/2mL N/A 25 mg/mL 14 d F syringe 14 d F - contains benzyl
27
500 mg/20mL alcohol
(Pfizer/Hospira) - do NOT use for
(RT)(PFL) 0.4–2 mg/mL NS, 24 h RT
27 high-dose
27
preservative D5W
27 regimens (e.g., 1-
2
12 g/m as a single
27
(100 mL* NS, D5W) dose)
- do NOT use for IT
27
injection
Mitomycin
28 28 28 28
20 mg 40 mL SWI 0.5 mg/mL 6 h RT, 72 h F syringe 6 h RT, 72 h F
(Accord)
28 28 28
(RT)(PFL) shake well **(PFL) **(PFL)
28
no preservative
Status)
Mitomycin
28 28 28 28
intravesical 40 mL SWI 0.5 mg/mL 6 h RT, 72 h F syringe 6 h RT, 72 h F
20 mg
28 28 28
(Accord) shake well **(PFL) **(PFL)
(RT)(PFL)
28
no preservative
29 29
10 mL SWI 2 mg/mL use immediately syringe use immediately after - may precipitate
after preparation preparation to prevent due to low
28 30 30,31
shake well to prevent precipitation solubility
30
precipitation - do NOT
30
refrigerate
Mitomycin
28 28 28 28
intraperitoneal 40 mL SWI 0.5 mg/mL 6 h RT, 72 h F 0.02-0.04 mg/mL NS:
28
20 mg 3 h RT, 18 h F
28 28 28
(Accord) shake well **(PFL) NS, sodium lactate
(RT)(PFL) sodium lactate:
28 28
no preservative 3 h RT, 6 h F
Mitomycin
32 32 32 32
20 mg 40 mL SWI 0.5 mg/mL 6 h RT, 72 h F syringe 6 h RT, 72 h F
(Teva/Novopharm)
32 32 32
(RT)(PFL) shake well **(PFL) **(PFL)
32
no preservative
Status)
Mitomycin
32 32 32 32
intravesical 40 mL SWI 0.5 mg/mL 6 h RT, 72 h F syringe 6 h RT, 72 h F
20 mg
32 32 32
(Teva/Novopharm) shake well **(PFL) **(PFL)
(RT)(PFL)
32
no preservative
29 29
10 mL SWI 2 mg/mL use immediately syringe use immediately after - may precipitate
after preparation preparation to prevent due to low
32 30 30,31
shake well to prevent precipitation solubility
30
precipitation - do NOT
30
refrigerate
Mitomycin
32 32 32 32
intraperitoneal 40 mL SWI 0.5 mg/mL 6 h RT, 72 h F 0.02-0.04 mg/mL NS:
32
20 mg 6 h RT, 18 h F
32 32 32
(Teva/Novopharm) shake well **(PFL) NS, sodium lactate
(RT)(PFL) sodium lactate:
32 32
no preservative 6 h RT, F
mitoXANTRONE
33 33 33
20 mg/10 mL N/A 2 mg/mL discard unused NS, D5W 24 h RT
33
(Fresenius Kabi) portion
(RT) Greater than or equal
33 33
no preservative to *50 mL
Status)
mitoXANTRONE
34 34
20 mg/10 mL N/A 2 mg/mL discard unused 0.2-0.6 mg/mL NS, 72 h F, 24 h RT
34 34
25 mg/12.5 mL portion D5W
34
30 mg/15 mL **(PFL)
(Pfizer/Hospira) Greater than or equal
34
(RT)(PFL) to *50 mL
34
no preservative
Nivolumab
35
40 mg/4 mL N/A 10 mg/mL discard unused 1-10 mg/mL NS, complete - administer with a
35 35
100 mg/10 mL portion D5W administration within 0.2 to 1.2 micron
35 35
(BMS) 8 h RT or 24 h F in-line filter
(F)(PFL) (50-100* mL) - discard if cloudy
35
do not shake **(PFL) or has pronounced
35
no preservative mix by gentle colour change
inversion; do not (should be clear to
35 35
shake pale yellow)
oBINutuzumab
36 36,38
1000 mg/40 mL N/A 25 mg/mL discard unused 100 mg: 24 h F, 48 h RT -once removed
37 36
(Hoffman-La Roche) portion in 100 mL NS from the fridge,
**
(F)(PFL) diluted product is
do not shake 900 mg: stable for an
36 36
no preservative in 250 mL NS additional 48 h
36,38
RT
36
1000 mg: - do NOT shake
36
in 250 mL NS - do NOT use
dextrose containing
36
solutions
Status)
Octreotide
39 39 39 39
50 mcg/mL N/A 50 mcg/mL Use within 4 h NS 24 h RT
100 mcg/mL
39
500 mcg/mL 100 mcg/mL volume adjusted to
(Omega) ensure a continuous
39
(F)(PFL) 500 mcg/mL infusion of octreotide
39 39
no preservative at 25 mcg/hour
Octreotide
39 39 39 39
multidose vial: N/A 200 mcg/mL 15 d F NS 24 h RT
1000 mcg/5 mL
(Omega) volume adjusted to
(F)(PFL) ensure a continuous
39
preservative infusion of octreotide
39
at 25 mcg/hour
Octreotide
40 40 40
50 mcg/mL N/A 50 mcg/mL discard unused SC syringe use within 4 h
40
100 mcg/mL portion
40
500 mcg/mL 100 mcg/mL
(Teva/Novopharm)
40 40 40
(F)(PFL) 500 mcg/mL infusion: NS 24 h RT
40
no preservative
Status)
Octreotide
40 40,41 40,41
multidose vial: N/A 200 mcg/mL 14 d F SC syringe use within 14 d F
1000 mcg/5 mL
(Teva/Novopharm)
40 40
(F)(PFL) infusion: NS 24 h RT
40
preservative
Octreotide
42 10,44,45 44
(SANDOSTATIN®) N/A 200 mcg/mL discard unused 50–200 mL NS 24 h RT
43
1000 mcg/5 mL portion
(Novartis) SC infusion: adjust
(F)(PFL) volume to ensure
42
preservative infusion rate of 25
44
mcg/h
Octreotide
10,45 44
(SANDOSTATIN®) N/A 50 mcg/mL discard unused 50-100 mL 24 h RT
44
50 mcg/1 mL 100 mcg/mL portion
42 44
100 mcg/1 mL 500 mcg/mL NS
500 mcg/1 mL
(Novartis) SC infusion: adjust
(F)(PFL) volume to ensure
42
no preservative infusion rate of 25
44
mcg/h
Status)
Octreotide
(SANDOSTATIN LAR®) 2 mL supplied 10 mg: 5 mg/mL discard unused deep intragluteal use within 4 h of initial - do NOT shake
44 44 7,44
10 mg diluent portion administration only reconstitution
20 mg 20 mg: 10 mg/mL
30 mg gently run 2 mL
44
(Novartis) down sides of the 30 mg: 15 mg/mL
(F)(PFL) vial; do NOT disturb
43
no preservative for 2–5 min, then
44
swirl moderately
record time of
reconstitution
Olaratumab
46 46
500 mg/50 mL N/A 10 mg/mL discard unused dilute to a final complete - do NOT shake
37,46
(Lilly) portion volume of 250 mL administration within
46
(F)(PFL) NS 24 h F, plus an
46
do not shake additional 12 h RT
46
no preservative do NOT use D5W or
other dextrose
46
containing solutions
46
gently invert to mix
Status)
Oxaliplatin
47
50 mg/10 mL N/A 5 mg/mL discard unused 250-500 mL D5W 0.2-0.4 mg/mL: - do NOT use
47
100 mg/20 mL portion 24 h RT aluminum-
47
200 mg/40 mL (0.2-0.7 mg/mL or containing needle,
47
(Hospira/Pfizer) 5 d F plus an syringe or tubing
47,49
(RT) do NOT use NS or additional 8 h RT
47
no preservative other chloride-
48
containing solutions 0.5–2 mg/mL:
24 h RT
do NOT use or
aluminum-containing 14 d F plus an
48 47,49
needle and syringe additional 8 h RT
Oxaliplatin
48 37,50 48
50 mg/10 mL N/A 5 mg/mL 2 d F, RT 0.2-0.7 mg/mL 0.2-2 mg/mL:
48
100 mg/20 mL 24 h RT, 48 h F
48
150 mg/30 mL 250-500 mL D5W
200 mg/40 mL
(Sandoz) do NOT use NS or
(RT)(PFL) other chloride-
48 48
no preservative containing solution
do NOT use
aluminum-containing
48
needle and syringe
Status)
Oxaliplatin
51
50 mg/10 mL N/A 5 mg/mL discard unused 250-500 mL D5W 0.2-2 mg/mL: - do NOT use
51 51
100 mg/20 mL portion 24 h RT, 48 h F aluminum-
51
200 mg/40 mL (0.2-0.7 mg/mL) containing needle,
51
(Teva) syringe or tubing
(RT)(PFL) do NOT use NS or
51
no preservative other chloride-
51
containing solution
do NOT use
aluminum-containing
51
needle and syringe
PACLitaxel
52
30 mg/5 mL N/A 6 mg/ mL 30 mg: 0.3-1.2 mg/mL in NS, complete - use non-DEHP
37,52 52
100 mg/16.7 mL 48 h RT D5W, D5NS, D5LR administration within bag and tubing with
52
300 mg/50 mL 27 h RT 0.22 micron in-line
52
(Accord) 100 mg: (e.g., 100-1000 mL)* filter
37,52
(RT)(PFL) 48 h RT - avoid excessive
52 52
no preservative shaking
300 mg:
52
24 h RT
Status)
PACLitaxel
54 37,55
30 mg/5 mL N/A 6 mg/mL 48 h RT 0.3-1.2 mg/mL in NS, complete - use non-DEHP
54
100 mg/16.7 mL D5W administration within bag and tubing with
54,56
300 mg/50 mL 27 h RT 0.22 micron in-line
54
(Biolyse) (e.g., 100-1000 mL)* filter
53
(RT)
54
no preservative
57 57
0.1 mg/mL in NS 44 h F, RT
56
0.012-0.12 mg/mL in 16 h RT
58
NS
devices with spikes

(e.g., chemo
dispensing pins) may
59
be used with vials
PACLitaxel
61 37,61,62
30 mg/5 mL N/A 6 mg/mL 48 h RT 0.3-1.2 mg/mL in NS, complete - use non-DEHP
100 mg/16.7 mL D5W, D5-NS, administration within bag and tubing with
61 61
150 mg/25 mL D5-LR 27 h RT 0.22 micron in-line
61
300 mg/50 mL filter
(Hospira) (e.g., 100-1000 mL)*
(RT)(PFL)
60
preservative
Status)
PACLitaxel,
63 63
nanoparticle, albumin- 20 mL NS 5 mg/mL use immediately in empty sterile PVC, 48 h F plus an - each vial contains
64
bound (nab) (RT) or non-PVC, or non- additional 8 h RT 900 mg human
63 63 63
100 mg - slowly direct 8hF DEHP infusion bag albumin
(Celgene) diluent against side - to prevent
63
(RT)(PFL) of vial (i.e., greater **(PFL) foaming, do NOT
63
no preservative than or equal to 1 inject NS directly
63
min) during onto the powder
63
reconstitution - some settling may
occur; use mild
- let stand for agitation to
63
greater than or resuspend
equal to 5 min to wet - administer using
63
powder a 15 micron filter
ONLY
- gently swirl or (NOTE:filters with a
invert for greater pore size less than
than or equal to 2 15 microns may
63
min cause filter
65,66
blockage)
Pamidronate
67 67
30 mg/10 mL N/A 3 mg/mL discard unused Less than or equal to 24 h RT - do NOT mix with
67 67
60 mg/10 mL portion 0.36 mg/mL NS, calcium containing
67 67
90 mg/10 mL D5W solutions
67
(Fresenius Kabi) 6 mg/mL
(RT)
67
no preservative
67
9 mg/mL
Status)
Pamidronate
68
30 mg/10 mL N/A 3 mg/mL discard unused 0.06–0.36 mg/mL in 24 h F followed by 24 h - do NOT mix with
68 68 68
60 mg/10 mL portion NS, D5W RT (total 48 h) calcium containing
90 mg/10 mL solution (e.g.,
68 68 68
(Hospira) 6 mg/mL **(PFL) Ringer’s)
(RT)
68
no preservative
68
9 mg/mL
Pamidronate
69 69
30 mg/10 mL N/A 3 mg/mL discard unused 0.06–0.36 mg/mL in 24 h F followed by 24 h - do NOT mix with
69 69 69
69 69 69
(Omega) 6 mg/mL **(PFL) Ringer’s)
(RT)
69
no preservative
69
9 mg/mL
Pamidronate
70
30 mg/10 mL N/A 3 mg/mL discard unused 0.06-0.36 mg/mL in 24 h F followed by 24 h - do NOT mix with
70 70 70
70 70 70
(Pfizer) 6 mg/mL **(PFL) Ringer’s)
(RT)
70
no preservative
70
9 mg/mL
Status)
Pamidronate
71 71 71
30 mg/10 mL N/A 3 mg/mL discard unused NS; D5W 24 h RT - do NOT mix with
41,71
60mg/10 mL portion calcium containing
71 71
(Sandoz Canada) 6 mg/mL Ringer’s)
RT
71
no preservative
71
9 mg/mL
PANitumumab
72 72,73
100 mg/5 mL N/A 20 mg/mL discard unused Less than or equal to 24 h F, 6 h RT - administer with
72
400 mg/20 mL portion 1000 mg: 0.2 or 0.22 micron
72 72
(Amgen) 100 mL NS in-line filter
(F)(PFL) - solution may
do not shake Greater than 1000mg: contain particulates
72 72
no preservative 150 mL NS which do not affect
72
product quality
72,73
1-10mg/mL - do not administer
72
if discoloured
Status)
pegaspargase
74 74
(pegylated N/A 750 units/mL discard unused IM: syringe: - do NOT shake
74
asparaginase E. coli) portion max volume: use within 4 h of vial
37,74
3750 units/5 mL 2 mL in children and puncture
(Shire) adolescents;
(F)(PFL) 3 mL in adults
do not shake
74
no preservative if volume greater than
above, use multiple
74
sites
IV: bag:
74
100 mL NS, D5W use within 4 h of vial
37,74
puncture
Pembrolizumab
75
100 mg/4 mL N/A 25 mg/mL discard unused 1-10 mg/mL complete - use a 0.2 to 5
37,75 75
(Merck) portion NS, D5W administration within micron in-line
75 75
(F)(PFL) 6 h RT, 24 h F filter
do not shake mix by gentle - allow vials and
75 75
no preservatives inversion diluted solutions to
come to RT prior to
75
use
- vials contain 0.25
75
mL overfill
Status)
Pembrolizumab
75 75 75
50 mg 2.3 mL SWI 25 mg/mL 6 h RT, 24 h F 1-10 mg/mL NS, complete - use 0.2 to 5
75
(Merck) D5W administration within 6 micron in-line
75 76
(F) direct diluent against h RT, 24 h F filter
75
no preservative side of vial during mix by gentle - allow
75
reconstitution to inversion reconstituted vials
75
avoid foaming and diluted
solutions to come
75
allow up to 5 to RT prior to use
minutes for bubbles - vials can be at RT
75
to clear for up to 24 h prior
75
to use
75
do NOT shake - vials contain 20%
75
overfill
Pemetrexed
77 77 77
100 mg 100 mg: 25 mg/mL 24 h F, RT 100 mL 24 h F, RT - do NOT mix with
77 77
500 mg 4.2 mL NS NS calcium containing
(Accord) solution (e.g.,
77
(RT) 500 mg: Ringer’s)
77 77
no preservative 20 mL NS
Pemetrexed
78 78 78
100 mg 100 mg: 25 mg/mL 24 h F, RT 100 mL 24 h F, RT - do NOT mix with
78 78
500 mg 4.2 mL NS NS calcium containing
(Eli Lilly) solution (e.g.,
79
(RT) 500 mg: Ringer’s)
78
no preservative 20 mL preservative-
78
free NS
Status)
PERTuzumab
80 80 80
420 mg/14 mL N/A 30 mg/mL discard unused 250 mL NS only 24 h F, RT - do NOT use
37,80
(Roche) portion dextrose containing
80 80
(F)(PFL) do NOT shake mix by gentle solutions
80
no preservative inversion to avoid
80
foaming
Plerixafor
81 81 41,82
24 mg/1.2 mL N/A 20 mg/mL discard unused SC syringe 48 hours RT
81
(sanofi-aventis) portion
(RT)
81
no preservative
Pralatrexate
83 83 84 83
20 mg/1 mL N/A 20 mg/mL discard unused syringe 24 h F, RT - do NOT dilute
2
40 mg/2 mL portion
84
(Servier) **(PFL)
(F)(PFL)
83
no preservative
Raltitrexed
85 85 85
2 mg 4 mL SWI 0.5 mg/mL 24 h F, RT 50-250 mL NS, complete
85
(Pfizer) D5W administration within
85
(F,RT)(PFL) 24 h F, RT
85
(no preservative)
Status)
Ramucirumab
86 86 86
100 mg/10 mL N/A 10 mg/mL discard unused 250 mL* NS 4 h RT, 24 h F - use 0.22 micron
86 86
500 mg/50 mL portion filter
87
(Eli Lilly) (0.4 – 4 mg/mL) - do NOT use
(F)(PFL) dextrose containing
86 86
(do not shake) gently invert to mix solutions
86
no preservative
86
do NOT shake
riTUXimab
88 89,90
100 mg/10 mL N/A 10 mg/mL discard unused 1-4 mg/mL NS, 24 h F, 12 h RT - once removed
88 88
500 mg/50 mL portion D5W from the fridge,
(Roche) compounded
(F)(PFL) (e.g., 250-500 mL)* product is stable
88 89,90
no preservative for 12h RT
riTUXimab
91 91 91
subcutaneous N/A 120 mg/mL discard unused SC syringe 48 h F plus 8 h RT - contains
91 91
1400 mg/11.7 mL portion hyaluronidase
1600 mg/13.4 mL - formulations are
(Roche) NOT
91
(F)(PFL) interchangeable
91
no preservative
Status)
romiDEPsin
92 92 92 92
10 mg 2.2 mL of supplied 5 mg/mL 8 h RT 500 mL NS 24 h RT - reconstituted
92,93
(Celgene Inc.) diluent solution will be
92 94
(RT) slightly viscous
37 92
no preservative swirl gently to mix - vials contain
overfill to allow for
full drug recovery
(drug vial contains
11 mg romidepsin;
diluent vial
contains 2.4 mL
92
diluent)
Siltuximab
95 95 95
100 mg 100 mg: 20 mg/mL 2 h RT 250 mL D5W complete - use 0.2 micron in-
95 95
400 mg 5.2 mL SWI administration within line filter
95
(Janssen) dilute to 250 mL final 6 h RT
(F)(PFL) 400 mg: volume by
95 95
no preservative 20 mL SWI withdrawing volume
from bag equal to
allow vial to come to volume of drug to be
95
room temperature added
prior to use (~30
95
minutes)
gently swirl, do NOT

95
shake
Status)
Streptozocin
96 96 96 96
1g 9.5mL NS, SWI, 100 mg/mL 48 h F, 24 h RT syringe 48 h F, 24 h RT
96
(Pfizer) D5W
(F)(PFL)
96 96
no preservative 50-500 mL* NS, 48 h F, 24 h RT
96
D5W, SWI
Temsirolimus
97,98 97,98 97,98
30 mg/1.2 mL 1.8 mL supplied 10 mg/mL 24 h RT 250 mL NS complete - use non-DEHP
97,98
(Wyeth) diluent administration within 6 bag and tubing with
97,98 97 97,98 97,98
(F)(PFL) **(PFL) h in-line filter
99
no preservative
Teniposide
100
50 mg/5 mL N/A 10 mg/mL discard unused 50 – 500 mL NS, 0.1-0.4 mg/mL: 24 h - do not refrigerate
100
(BMS) portion D5W for a final RT - use non-DEHP
100
(RT) concentration of 0.1-1 bag and tubing
100 100
preservative mg/mL 1 mg/mL: complete - do not use if
100,101
administration within 4 precipitates
h of preparation - contains DMA***
100,101
RT - excessive
agitation may
cause
100
precipitation
Status)
Thiotepa
102 102 102
15 mg 15 mg: 10 mg/mL 8hF reconstituted solution 4 h RT, 24 h F - do not use if
102
100 mg 1.5 mL SWI is hypotonic and must precipitates are
102
(Adienne/Methapharm) be further diluted with present
102
(F) 100 mg: NS prior to use - reconstituted
102 102
no preservative 10 mL SWI solution may be
doses ≤ 500 mg: used if
102
to remove haze, 500 mL NS or with an opalescent
filter through 0.22 appropriate volume to - administer with
micron filter after achieve 0.5-1 mg/mL 0.2 micron inline
103 102 102
reconstitution concentration filter
record time of doses > 500 mg:

102
reconstitution 1000 mL NS
Status)
Thiotepa
102 102 26
IT injection diluents containing 10 mg/mL 8hF qs to 6 mL with use within 4 h of initial - auxiliary info :
25 2
15 mg preservatives should preservative free NS reconstitution “IT”
100mg NOT be used for - label to include
(Adienne/Methapharm) intrathecal route in full (i.e.,
104
(F) administration INTRATHECAL
102
no preservative injection) attached
15 mg: to both syringe and
102 26
1.5 mL SWI outer ziplock bag
- do not use if
100 mg: precipitates are
102 102
10 mL SWI present
- reconstituted
to remove haze, solution may be
filter through 0.22 used if
102
micron filter after opalescent
103
reconstitution
record time of
reconstitution
Thyrotropin alfa
105 105 105 105 105
1.1 mg 1.2 mL SWI 0.9 mg/mL 24 h F syringe 24 h F
(Genzyme)
105
(F)(PFL) swirl contents
105
no preservative
do NOT shake
Status)
Tocilizumab
106 106
80 mg/4 mL N/A 20 mg/mL discard unused 100 mL NS complete - to prevent
106
200 mg/10 mL portion administration within foaming: slowly
106
400 mg/20 mL dilute to final volume 24 h F, RT add drug to
(Roche) by withdrawing infusion bag and
(F)(PFL) volume from bag bring to room gently invert bag to
106 106
no preservative equal to volume of temperature prior to mix
106 106
drug to be added administration
106
gently invert to mix
Topotecan
107 2,107
4 mg/4 mL N/A 1 mg/mL discard unused 0.025-0.5 mg/mL 14 d F, 48 h RT
2,107
(Accord) portion
(RT)(PFL) 50-100 mL NS,
107 107
no preservative D5W
Topotecan
108 108 108
1 mg 1 mg: 1 mg/mL 24 h F,RT 0.02-0.5 mg/mL 24 F, RT
108
4 mg 1.1 mL SWI
(Actavis) 50-100 mL NS,
108
(RT)(PFL) 4 mg: D5W
108 108
no preservative 4 mL SWI
Topotecan
109 109
4 mg/4 mL N/A 1 mg/mL discard unused 0.02-0.5 mg/mL 24 h F, RT
2,109
(Pfizer/Hospira) portion
(F)(PFL) 50-100 mL NS,
109 109
no preservative D5W
Status)
Topotecan
110 110
4 mg/4 mL N/A 1 mg/mL discard unused 0.02-0.5 mg/mL 24 h F
110
(Sandoz) portion
110
(F)(PFL) 50-100 mL NS, **(PFL)
110 110
no preservative D5W
Trastuzumab
111 37 111 111 111
(HERCEPTIN®) 20 mL supplied 21 mg/mL 14 d F 250 mL NS only 24 h F, RT - do NOT shake
111
440 mg BWI
(Roche) do NOT use dextrose
111
(F) swirl vial gently; containing solutions
111
preservative allow to stand
undisturbed for 5
111
min
Status)
Trastuzumab
112 112 112
Emtansine 100 mg vial: 20 mg/mL 24 h F 250 mL NS or ½NS 24 h F - do not use if
112 112
(KADCYLA®) 5 mL SWI only reconstituted
112 112
100 mg do NOT freeze do NOT freeze solution contains
112
160 mg 160 mg vial: do NOT shake visible particulates
112
(Roche) 8 mL SWI or is cloudy or
112
(F)(PFL) discolored
112
no preservative swirl gently until - dextrose 5%
completely dissolved solutions cause
aggregation of the
112
do NOT shake protein; do not
dilute with dextrose
containing
112
solutions
- use a 0.2 micron
in-line filter or 0.22
micron
polyethersulfane
(PES) filter to
administer
infusions prepared
in NS; filter is
optional for
solutions in 0.45%
112
NS
Status)
TRC105 (Carotuximab)
113 114
100 mg/4 mL N/A 25 mg/mL discard unused 0.6 – 10 mg/mL NS complete infusion - use a 0.2 micron
37
200 mg/8 mL portion within 8 h RT, 24 h in-line filter for
113,114 113
400 mg/16 mL invert gently to mix F administration
(Tracon)
(F)(PFL)
113
no preservative
Treosulfan
115 7,115 116 7,115
1g pre-heat SWI to 50 mg/mL 48 h RT undiluted 48 h RT - compatible with
5g 30°C (not higher) polytetrafluoroethyl
115
(medac) shake vial carefully dilute with NS or D5W ene filters
(RT) before adding the in empty infusion bag - may require
115
no preservative warmed SWI for final concentration vigorous shaking to
115 115
1 g vial: 20 mL SWI, = 20 mg/mL reconstitute
while slightly
shaking vial and
syringe; continue
shaking the
reconstituted
solution for another
115
2 min
5 g vial: 100 mL
SWI, while slightly
shaking vial and
syringe; continue
shaking the
reconstituted
solution for another
115
2 min
Status)
vinBLAStine
117 118 119,120
10 mg/10 mL N/A 1 mg/mL discard unused 25-50 mL NS, D5W 24 h F, RT - auxiliary info:
117
(Hospira) portion WARNING: FOR
(F)(PFL) INTRAVENOUS
117
no preservative USE ONLY –
FATAL IF GIVEN
BY OTHER
121,122
ROUTES
vinBLAStine
123
10 mg/10 mL N/A 1 mg/mL discard unused 25-50 mL NS, use within 4 h of initial - auxiliary info:
123 118,124 37
(Teva) portion D5W puncture WARNING: FOR
(F)(PFL) INTRAVENOUS
123
no preservative USE ONLY –
FATAL IF GIVEN
BY OTHER
121,122
ROUTES
Status)
vinCRIStine
125 125 125 125
2 mg/2 mL N/A 1 mg/mL 8 h F, RT 50 mL* NS, D5W 24 h F, 6 h RT - auxiliary info:
5 mg/5 mL WARNING: FOR
125
(Hospira) **(PFL) INTRAVENOUS
(F)(PFL) USE ONLY –
125
no preservative FATAL IF GIVEN
BY OTHER
121,122
ROUTES
- for ULYEPOCHR
protocol, see entry
for EPOCHR
(3-in-1 solution
containing
etoposide,
DOXOrubicin,
vinCRIStine)
Status)
vinCRIStine
126 126 126
1 mg/1 mL N/A 1 mg/mL 8 h F, RT 0.01-0.1 mg/mL NS, 24 h F, RT - auxiliary info:
126
2 mg/2 mL D5W WARNING: FOR
5 mg/5 mL INTRAVENOUS
(Teva) 25-50 mL NS, D5W
127
USE ONLY –
(F)(PFL) FATAL IF GIVEN
126
no preservative BY OTHER
121,122
ROUTES
- for ULYEPOCHR
protocol, see entry
for EPOCHR
(3-in-1 solution
containing
etoposide,
DOXOrubicin,
vinCRIStine)
Vinorelbine
128 128 128
10 mg/1 mL N/A 10 mg/mL discard unused 0.5-2.0 mg/mL 24 h F, RT - auxiliary info:
128
50 mg/5mL portion WARNING: FOR
(Fresenius Kabi) NS, D5W, ½NS, INTRAVENOUS
(F)(PFL) D5-½NS, Ringer’s, USE ONLY –
128 128
no preservative Ringer’s Lactate FATAL IF GIVEN
BY OTHER
121,129
ROUTES
Status)
Vinorelbine
130 130 130
10 mg/1 mL N/A 10 mg/mL discard unused 0.5-2.0 mg/mL 24 h F, RT - auxiliary info:
2
50 mg/5 mL portion WARNING: FOR
(GMP) 50 mL* NS, D5W, INTRAVENOUS
(F)(PFL) ½NS, D5-½NS, USE ONLY –
130
no preservative Ringer’s, Ringer’s FATAL IF GIVEN
130
Lactate BY OTHER
121,129
ROUTES
Vinorelbine
131 131 131
10 mg/1 mL N/A 10 mg/mL discard unused 0.5–2.0 mg/mL 24 h F, RT - auxiliary info:
131
(Pfizer/Hospira) 50 mL* NS, D5W, INTRAVENOUS
131
131
Lactate BY OTHER
121,129
ROUTES
Vinorelbine
132 132 132
10 mg/1 mL N/A 10 mg/mL discard unused 0.5–2.0 mg/mL 24 h F, RT - auxiliary info:
132
(Teva) 50 mL* NS, D5W, INTRAVENOUS
132
132
Lactate BY OTHER
121,129
ROUTES
Status)
Zoledronic acid
133 133
4 mg/5 mL N/A 0.8 mg/mL discard unused 100 mL NS, D5W complete infusion - do NOT mix with
133
(Dr Reddy’s) portion within 24 h of calcium containing
133 133
(RT) preparation solutions
133
no preservative
Refrigerate diluted
product if not used
immediately after
preparation; bring to
RT prior to
133
administration
Zoledronic acid
134 134
134
(Marcan) portion within 24 h of calcium containing
134
(RT) preparation solutions (e.g.,
134
no preservative Lactated
134
Refrigerate diluted Ringer’s)
product if not used
immediately after
RT prior to
134
administration
Status)
Zoledronic acid
135 135
135
(MDA) portion within 24 h of calcium containing
135 135
(RT) preparation solutions
135
no preservative
Refrigerate diluted
product if not used
immediately after
RT prior to
135
administration
Zoledronic acid
136 136
(ZOMETA) N/A 0.8 mg/mL discard unused 100 mL NS, D5W complete infusion - do NOT mix with
37
4 mg/ 5 mL portion within 24 h of calcium containing
136 136
(Novartis) preparation solutions
(RT)
136
no preservative Refrigerate diluted
product if not used
immediately after
RT prior to
136
administration
Status)
Zoledronic acid
137 137
4 mg/5 mL N/A 0.8 mg/mL discard unused 100 ml NS, D5W complete infusion - do NOT mix with
137
(Sandoz) portion within 24 h of calcium- or other
137
(RT) preparation divalent cation-
137
no preservative containing infusion
Refrigerate diluted solutions (e.g.,
product if not used Lactated
137
immediately after Ringer’s)
RT prior to
137
administration
* Suggested volume based on usual dose range and any concentration range of stability data
** Protect from light means minimizing exposure to direct sunlight over a storage period. More specific information on protection from light (eg, protecting container and tubing during
administration) will be indicated in the Under the Special Precautions/Notes column.
*** Contains DMA (N,N dimethylacetamide). Product may be incompatible with closed system transfer devices such as ChemoLock.
Centres are not to change content locally. All suggestions for change are to forwarded to the Cancer Drug Manual staff.
Explanatory Notes:
 Stability data assumes products prepared using standard aseptic technique in biological safety cabinet at low risk for contamination according to the
138,139
classification outlined in USP 797.
 Vial stability: Stability of solution after first puncture or reconstituted solution.
 Storage temperature: If information states same stability with refrigerator and room temperature storage, then fridge stability is bolded as preferred (ie, to
minimize growth of micro-organisms).
 Discard unused portion: Unused portion from single use vials should be discarded at the end of the day.
 “overfill known” is stated if the manufacturer states overfill that is present is within acceptable limits.
 “Complete administration within __” is stated if the manufacturer specifies that the infusion must be completed in a specific time frame following preparation,
usually including entire time required for preparation (from first puncture), storage, and administration of infusion.
Abbreviations:
BWI = bacteriostatic water for injection

CIVI: ambulatory pump = Continuous Intravenous Infusion (e.g., elastomeric infusor)
D5W = dextrose 5% in water
DMA = N,N dimethylacetamide
F = refrigerate
Non-DEHP = not containing Di(2-ethylhexyl) phthalate (DEHP)
NS = normal saline
PFL = protect from light
RT = room temperature
SWI = sterile water for injection
References:
1. Generic Medical Partners Inc. Leucovorin calcium injection product monograph. Toronto, Ontario; 13 August 2018.
2. BC Cancer. Provincial Pharmacy Directive Number II-20: Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer; 5 December 2018.
3. Pfizer Canada Inc. Leucovorin calcium injection product monograph. Kirkland, Quebec; 21 June 2018.
4. Teva Canada Limited. Leucovorin calcium injection® product monograph. Toronto, Ontario; 5 May 2014.
5. Hospira Healthcare Corporation. LEUCOVORIN CALCIUM INJECTION® product monograph. Saint-Laurent, Quebec; 7 June 2007.
6. Novopharm Limited (Teva). LEUCOVORIN CALCIUM® Injection product information package. Toronto, Ontario; undated.
7. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 6 January 2006.
8. Jenny Yeung. Medical Information Specialist, Teva Canada. Personal communication. 12 April 2017.
9. GlaxoSmithKline Inc. Alkeran Package Insert. Mississauga, Ontario; Montreal, Quebec; 2004.
10. Trissel LA. Handbook on Injectable Drugs. 13th ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2005.
11. Baxter Corporation. UROMITEXAN® product monograph. Mississauga, Ontario; 6 August 2013.
12. Mona Ghobros BPharm MSc. Medical Information, Baxter Corporation. Personal communication. 29 November 2018.
13. Trissel's® 2 Clinical Pharmaceutics Database (database on the Internet). Mesna. Lexi-Comp Inc.; created by Lawrence A. Trissel, Available at: http://online.lexi.com. Accessed 29
November 2018.
14. Fresenius Kabi Canada Ltd. Mesna for injection product monograph. Richmond Hill, Ontario; 21 December 2017.
15. BC Cancer. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer; 19 September 2007.
16. Fresenius Kabi Canada Ltd. Mesna for injection product monograph. Richmond Hill, Ontario; 30 March 2015.
17. Accord Healthcare Inc. Methotrexate injection product monograph. Kirkland, Quebec; 6 April 2018.
18. BC Cancer Agency Miscellaneous Origins Tumour Group. (MOHDMTX) BCCA Protocol Summary for Treatment of Meningeal Disease (Miscellaneous Tumour Origins) using High
Dose Methotrexate with Leucovorin Rescue. Vancouver, British Columbia: BC Cancer Agency; 1 Jan 2013.
19. BC Cancer Agency Sarcoma Tumour Group. (SAHDMTX) BCCA Protocol Summary for Treatment of Osteosarcoma Using High Dose Methotrexate with Leucovorin Rescue.
Vancouver, British Columbia: BC Cancer Agency; 1 Nov 2012.
20. BC Cancer Agency Lymphoma Tumour Group. (LYHDMRP) BCCA Protocol Summary for Treatment of Primary Intracerebral Lymphoma with High Dose Methotrexate and
riTUXimab. Vancouver, British Columbia: BC Cancer Agency; 1 Jun 2014.
21. BC Cancer Agency Lymphoma Tumour Group. (LYHDMTXP) BCCA Protocol Summary for Treatment of Primary Intracerebral Lymphoma with High Dose Methotrexate.
Vancouver, British Columbia: BC Cancer Agency; 1 Jun 2014.
22. BC Cancer Agency Lymphoma Tumour Group. (LYHDMTXR) BCCA Protocol Summary for Treatment of Leptomeningeal Lymphoma or Recurrent Intracerebral Lymphoma with
High Dose Methotrexate. Vancouver, British Columbia: BC Cancer Agency; 1 Jun 2014.
23. Mayne Pharma Canada. Methotrexate Product Monograph. Montreal, Quebec; December 2003.
24. BC Cancer Lymphoma Tumour Group. (LYIT) BC Cancer Protocol Summary for Treatment of Lymphoma using Intrathecal Methotrexate and Cytarabine. Vancouver, British
Columbia: BC Cancer; 1 June 2014.
25. BC Cancer Miscellaneous Origin Tumour Group. (MOIT) BC Cancer Protocol Summary for Solid Tumours using Intrathecal Methotrexate and/or Thiotepa and/or Cytarabine.
Vancouver, British Columbia: BC Cancer; 1 October 2018.
26. BC Cancer. Systemic Therapy Policy and Procedure III-50: Administration of High Alert Medications by the Intrathecal Route via Lumbar Puncture or Ommaya Reservoir.
Vancouver, British Columbia; 1 May 2019.
27. Pfizer Canada Inc. Methotrexate injection product monograph. Kirkland, Quebec; 13 October 2017.
28. Accord Healthcare Inc. Mitomycin product monograph. Kirkland, Quebec; 7 June 2017.
29. Au JLS, Badalament RA, Wientjes MG, et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst April 18,
2001;93(8):597-604.
30. Jessie LS Au PharmD PhD. Professor, Ohio State University. Personal communication. 14 May 2007.
31. Myers AL, Zhang Y, Kawedia JD, et al. Solubilization and stability of mitomycin C solutions prepared for intravesical administration. Drugs R D 2017;17:297-304.
32. Teva Canada Limited. Mitomycin for injection® product monograph. Toronto, Ontario; 30 June 2017.
33. Fresenius Kabi Canada Ltd. Mitoxantrone injection® product monograph. Richmond Hill, Ontario; 28 September 2016.
34. Pfizer Canada Inc. Mitoxantrone injection product monograph. Kirkland, Quebec; 17 October 2018.
35. Bristol-Myers Squibb Canada. OPDIVO® product monograph. Montreal, Quebec; 16 July 2018.
36. Hoffmann-La Roche Ltd. GAZYVA® product monograph. Mississauga, Ontario; 21 December 2015.
37. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 19 September
2007.
38. Anna Sivojelezova MSc. Drug Information Associate, Hoffmann-La Roche Ltd. Personal communication. 24 April 2015.
39. Omega Laboratories Ltd. Octreotide Acetate Injection product monograph. Montreal, Quebec; 23 July 2010.
40. Novopharm Limited. Octreotide Injection Product Monograph. Scarborough, Ontario; 15 March 2007.
41. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 19 September
2007.
42. Novartis Pharmaceuticals Canada Inc. SANDOSTATIN® Product Monograph. Dorval, Quebec; 9 January 2001.
43. Repchinsky C, editor. Sandostatin LAR monograph, Compendium of Pharmaceuticals and Specialties. Ottawa, Ontario: Canadian Pharmacists Association; 2005. p. 1912-1916.
44. Repchinsky C editor. Compendium of Pharmaceuticals and Specialties. 12th ed. Ottawa, Ontario: Canadian Pharmacists Association; 2004.
45. Vancouver Hospital and Health Sciences Centre Pharmacy Department. Octreotide. Parenteral drug therapy manual. Vancouver, BC; February 2002.
46. Eli Lilly Canada Inc. LARTRUVO® product monograph. Toronto, Ontario; 23 November 2017.
47. Pfizer Canada Inc. Oxaliplatin injection product monograph. Kirkland, Quebec; 31 May 2017.
48. Sandoz Canada Inc. Oxaliplatin injection product monograph. Boucherville, Quebec; 12 August 2015.
49. Medical Information Pfizer Canada Inc. Personal communication. 6 June 2017.
50. Katryn Vosburg. Drug Information & Pharmacovigilance Specialist, Sandoz Canada Inc. Personal communication. 26 February 2016.
51. Teva Canada Limited. Teva-Oxaliplatin injection® product monograph. Toronto, Ontario; 11 September 2015.
52. Accord Healthcare Inc. Paclitaxel injection product monograph. Markham, Ontario; 13 August 2012.
53. Claude Mercure. Production Manager Biolyse Pharma Corporation. Personal communication. 21 December 2009.
54. Biolyse. PACLITAXEL FOR INJECTION® product monograph. St. Catherines, Ontario; 2 December 2005.
55. Claude Mercure. Manager, Biolyse Pharma Corporation. Personal communication. 24 June 2014.
56. Zeng Z, Lazakovitch E. Study IR 120: Physical and Chemical Stability Study of Paclitaxel for Injection in 0.9 % Sodium Chloride in concentration range 0.012-0.12 mg/mL. Biolyse
Pharma March 2010.
57. Mercure C. Stability of 0.1 mg/mL of paclitaxel for injection in sodium chloride (0.9%) solution. St Catharines, Ontario: Biolyse Pharma; 2 February 2007.
58. Xu Q, Trissel LA, Martinez JF. Stability of paclitaxel in 5% dextrose injection or 0.9% sodium chloride injection at 4, 22, or 32 degrees C. Am J Hosp Pharm Dec 15,
1994;51(24):3058-60.
59. Lisa Tavano. Biolyse Pharma Corporation. Personal communication. 14 May 2012.
60. Robyn MacKenzie. Area Manager, Hospira Healthcare Corporation. Personal communication. 4 April 2012.
61. Hospira Healthcare Corporation. PACLITAXEL FOR INJECTION® product monograph. Saint-Laurent, Quebec; 1 September 2009.
62. Rose Toussaint. Hospira Canada Healthcare Corporation. Personal communication. 4 April 2012.
63. Celgene Inc. ABRAXANE® product monograph. Mississauga, Ontario; 24 July 2014.
64. Aisling Cahill. Drug Safety and Medical Information Specialist. Celgene Inc. Personal communication. 23 April 2015.
65. Celgene Europe Limited. ABRAXANE® product monograph. Uxbridge, UK; 11 January 2013.
66. Celgene Inc. ABRAXANE® product monograph. Mississauga, Ontario; 18 January 2016.
67. Pharmaceutical Partners of Canada. Pamidronate Disodium For Injection product monograph. Richmond Hill, Ontario; 18 January 2010.
68. Mayne Pharma (Canada) Inc. Pamidronate Package Insert. Montreal, Quebec; 2002.
69. Omega Laboratories Ltd. Pamidronate Disodium product monograph. Montreal, Quebec; 06 June 2005.
70. Pfizer Canada ULC. Pamidronate disodium for injection product monograph. Kirkland, Quebec; 11 December 2018.
71. Sandoz Canada Inc. Pamidronate injection product monograph. Boucherville, Quebec; 28 February 2006.
72. Amgen Canada. VECTIBIX® product monograph. Mississauga, Ontario; 5 March 2009.
73. Diane Lord. Medical Information Department, Amgen Canada Inc. Personal communication. 19 June 2009.
74. Shire Pharma Canada ULC. ONCASPAR® product monograph. Toronto, Ontario; 20 April 2018.
75. Merck Canada Inc. KEYTRUDA® product monograph. Kirkland, Quebec; 21 February 2018.
76. Merck Canada Inc. KEYTRUDA® product monograph. Kirkland, Quebec; 5 February 2016.
77. Accord Healthcare Inc. Pemetrexed disodium for injection product monograph. Kirkland, Quebec; 12 March 2015.
78. Eli Lilly Canada. Pemetrexed product information. Toronto, Ontario; 2008.
79. Eli Lilly Canada Inc. ALIMTA® Product Monograph. Toronto, Ontario; 21 May 2004.
80. Hoffmann-La Roche Limited. PERJETA® product monograph. Mississauga, Ontario; 12 April 2013.
81. sanofi-aventis Canada Inc. MOZOBIL® product monograph. Laval, Quebec; 8 October 2014.
82. Maureen Coughlin BSc Pharm. Solutions in Health Inc. (acting as an authorized agent of sanofi-aventis and ). Personal communication. 24 May 2017.
83. Servier Canada Inc. FOLOTYN® product monograph. Laval, Quebec; 19 October 2018.
84. Marjolaine Migeon PharmD. Servier Canada Medical Information. Personal communication. 24 September 2019.
85. Pfizer Canada Inc. TOMUDEX® product monograph. Kirkland, Quebec; 8 August 2017.
86. Eli Lilly Canada Inc. CYRAMZA® product monograph. Toronto, Ontario; 16 July 2015.
87. Marilyn Bain BScN. Senior Medical Information Associate, Eli Lilly Canada Inc. Personal communication. 16 January 2017.
88. Hoffmann-La Roche Ltd. RITUXAN® product monograph. Mississauga, Ontario; 29 March 2012.
89. Hoffmann-La Roche Ltd. RITUXAN® product monograph. Mississauga, Ontario; 29 May 2014.
90. Diana Fung. Pharmacist, Hoffmann-La Roche Medical Information. Personal communication. 16 July 2014.
91. Hoffmann-La Roche Ltd. RITUXAN® SC product monograph. Mississauga, Ontario; 21 March 2018.
92. Celgene Inc. ISTODAX® product monograph. Mississauga, Ontario; 13 December 2016.
93. Celgene Inc. INFO Rx ISTODAX® (romidepsin) for Injection. Mississauga, Ontario; 10 July 2017.
94. Aisling Cahill. Drug Safety and Medical Information Specialist. Celgene Inc. Personal communication. 17 July 2015.
95. Janssen Inc. SYLVANT® product monograph. Toronto, Ontario; 6 January 2016.
96. Pharmacia Canada Inc. Zanosar Package Insert. Mississauga, Ontario; March 2003.
97. Wyeth Canada. TORISEL® product monograph. Montreal, Canada; 16 October 2008.
98. McEvoy GK, editor. AHFS 2008 Drug Information. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc. p. 1226-1228.
99. Anna Sivojelezova M.Sc. Medical Information Associate, Wyeth. Personal communication. 6 January 2010.
100. Bristol-Myers Squibb Canada. VUMON® product monograph. St. Laurent, Quebec; 26 October 2004.
101. Trissel's®2 IV Compatibility (database on the Internet). Teniposide. Thomson Reuters MICROMEDEX® 2.0, updated periodically. Available at: http://www.micromedex.com.
Accessed 27 April 2011.
102. Adienne SA. TEPADINA® product monograph. Lugano, Switzerland; 28 March 2017.
103. AHFS Drug Information® (database on the Internet). Thiotepa. Lexi-Comp Inc., 27 February 2018. Available at: http://online.lexi.com. Accessed 21 August 2018.
104. Hematology/Oncology Pharmacy Association. HOPA News Clinical Pearls: Intrathecal Chemotherapy: Focus on Drugs, Dosing, and Preparation. 13(4) ed. Chicago, Illinois, USA:
Hematology/Oncology Pharmacy Association; 2016.
105. Genzyme Canada. Thyrogen Product Monograph. Mississauga, Ontario; 2004.
106. Hoffmann-La Roche Limited. ACTEMRA® product monograph. Mississauga, Ontario; 27 October 2017.
107. Accord Healthcare Inc. Topotecan hydrochloride for injection product monograph. Kirkland, Quebec; 9 May 2019.
108. Actavis Pharma Company. Topotecan for injection product monograph. Mississauga, Ontario; 3 January 2018.
109. Pfizer Canada Inc. Topotecan hydrochloride for injection product monograph. Kirkland, Quebec; 5 January 2018.
110. Sandoz Canada Inc. Topotecan injection product monograph. Boucherville, Quebec; 5 September 2014.
111. Hoffman-La Roche Limited. HERCEPTIN® product monograph. Mississauga, Ontario; 16 November 2012.
112. Hoffmann-La Roche Limited. KADCYLA® product monograph. Mississauga, Ontario; 11 September 2013.
113. Tracon Pharmaceuticals Inc. TRC105 (carotuximab) investigational brochure. San Diego, California; 14 February 2017 (version 10.0).
114. Tracon Pharmaceuticals Inc. Clincial Protocol: A Phase 2A Study of TRC105 (with Option to Add Bevacizumab) in Patients with Refractory Gestastional Trophoblastic Neoplasia
(GTN). San Diego, California; 20 September 2016 Amendment #3.
115. medac UK. TREOSULFAN injection® product monograph. Hamburg, Germany; 24 June 2008.
116. Henrik Fenger. Management Associate, International Division medac. Personal communication. 03 March 2010.
117. Mayne Pharma (Canada) Inc. Vinblastine product monograph. Kirkland, Quebec; 10 August 2003.
118. Lexi-Drugs® (database on the Internet). VinBLAStine. Lexi-Comp Inc., 3 November 2014. Available at: http://online.lexi.com. Accessed 20 November 2014.
119. Jan Barrow. Supervisor, Hospira Canada Clinical Support. Personal communication. 03 December 2007.
120. Tanya Leduc. Pharmacist. Acting editor, BC Cancer Agency Cancer Drug Manual. Personal communication. 18 Dec 2007.
121. World Health Organization. Information Exchange System: Alert No. 115 (QSM/MC/IEA.115). Geneva, Switzerland: World Health Organization; 18 July 2007.
122. BCCA Provincial Systemic Therapy Program. Labeling of vinca alkaloid syringes. Policy # V-40. Vancouver, British Columbia: BC Cancer Agency; 27 May 1999.
123. Teva Canada Limited. Vinblastine sulfate injection® product monograph. Toronto, Ontario; 1 February 2013.
124. Trissel's®2 IV Compatibility (database on the Internet). Vinblastine sulfate. Thomson Reuters MICROMEDEX® 2.0, updated periodically. Available at:
http://www.micromedex.com. Accessed 8 June 2015.
125. Mayne Pharma (Canada) Inc. Vincristine Package Insert. Montreal, QC; Undated.
126. Teva Canada Limited. Vincristine sulfate injection® product monograph. Scarborough, Ontario; 27 March 2014.
127. Lexi-Drugs® (database on the Internet). VinCRIStine. Lexi-Comp Inc., 3 June 2015. Available at: http://online.lexi.com. Accessed 9 June 2015.
128. Pharmaceutical Partners of Canada. Vinorelbine Injection product monograph. Richmond Hill, Ontario; 15 January 2008.
129. BC Cancer Provincial Systemic Therapy Program. Policy V-40: Dispensing and Labelling of Vinca Alkaloid Preparations. Vancouver, British Columbia: BC Cancer; 1 April 2015.
130. Generic Medical Partners Inc. Vinorelbine Injection product monograph. Toronto, Ontario; 3 September 2014.
131. Pfizer Canada Inc. Vinorelbine Tartrate for Injection product monograph. Kirkland, Quebec; 21 July 2017.
132. Teva Canada Limited. Vinorelbine tartrate for Injection product monograph. Toronto, Ontario; 20 March 2014.
133. Innomar Strategies Inc. (for Dr. Reddy's Laboratories Limited). Zoledronic acid for injection concentrate® product monograph. Oakville, Ontario; 11 March 2015.
134. Marcan Pharmaceuticals Inc. Zoledronic acid concentrate for injection product monograph. Ottawa, Ontario; 5 February 2018.
135. MDA Inc. Zoledronic acid for injection product monograph. Mississauga, Ontario; 11 August 2015.
136. Novartis Pharmaceuticals Canada Inc. ZOMETA® product monograph. Dorval, Quebec; 26 July 2013.
137. Sandoz Canada Inc. Zoledronic Acid - Z® product monograph. Boucherville, Quebec; 02 December 2016.
138. The United States Pharmacopeia (USP). General Chapter 797: Pharmaceutical compounding - sterile preparations. USP 27-NF 22. Rockville, Maryland: The United States
Pharmacopeial Convention, Inc.; 2004.
139. Kastango ES. The ASHP discussion guide for compounding sterile preparations. Bethesda (MD): American Society of Health-System Pharmacists, Inc.; 2004. p. 5.

Chemo Stability Chart - LtoZ

Uploaded by

Copyright:

Available Formats

You might also like

Chemo Stability Chart - LtoZ

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Chemo Stability Chart - LtoZ

Uploaded by

Copyright:

Available Formats

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART

(e.g., 50-250 mL*) D10W, D5NS:

(e.g., 50-250 mL*)

0.06 - 0.4 mg/mL NS, NS:

0.06 - 1 mg/mL Ringer’s, LR:

high dose use within 24 h RT of

high dose use within 24 h RT of

devices with spikes

gently swirl, do NOT

record time of doses > 500 mg:

BWI = bacteriostatic water for injection

You might also like